Ketamine as an antidepressant: overview of its mechanisms of action and potential predictive biomarkers
Open accessThe DOI matches its Crossref record; 222 of the 224 references it cites were found in a registry or an index; 43 of the 250 sources its claims cite were checked for support.
Abstract
Ketamine, a drug introduced in the 1960s as an anesthetic agent and still used for that purpose, has garnered marked interest over the past two decades as an emerging treatment for major depressive disorder. With increasing evidence of its efficacy in treatment-resistant depression and its potential anti-suicidal action, a great deal of investigation has been conducted on elucidating ketamine’s effects on the brain. Of particular interest and therapeutic potential is the ability of ketamine to exert rapid antidepressant properties as early as several hours after administration. This is in stark contrast to the delayed effects observed with traditional antidepressants, often requiring several weeks of therapy for a clinical response. Furthermore, ketamine appears to have a unique mechanism of action involving glutamate modulation via actions at the N-methyl-D-aspartate (NMDA) and [Formula: see text]-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors, as well as downstream activation of brain-derived neurotrophic factor (BDNF) and mechanistic target of rapamycin (mTOR) signaling pathways to potentiate synaptic plasticity. This paper provides a brief overview of ketamine with regard to pharmacology/pharmacokinetics, toxicology, the current state of clinical trials on depression, postulated antidepressant mechanisms and potential biomarkers (biochemical, inflammatory, metabolic, neuroimaging sleep-related and cognitive) for predicting response to and/or monitoring of therapeutic outcome with ketamine.
Overview
CoChat Summary
TL;DR
This review summarizes ketamine’s pharmacology, clinical trial evidence, adverse effects, antidepressant mechanisms, and candidate biomarkers for treatment-resistant depression. It highlights rapid but transient antidepressant and anti-suicidal effects, with a proposed glutamate–AMPA–BDNF–mTORC1 synaptic plasticity mechanism, while noting limited long-term and biomarker data.
Key findings
- Ketamine produces rapid antidepressant effects within 2–4 h, with 60–70% response rates in treatment-resistant depression (TRD); effects are transient, lasting an average of 1 week after a single infusion and 18–19 days after repeated infusions. Retrospective real-world data showed a 44% response rate after six intravenous ketamine treatments in complex, ultra-resistant patients.
- Its mechanism is more complex than NMDA receptor antagonism: ketamine preferentially antagonizes NMDA receptors on GABA interneurons, causing disinhibition of glutamatergic neurons, a glutamate surge, AMPA receptor activation, and downstream BDNF/mTORC1 signaling that potentiates synaptic plasticity. Other NMDA antagonists such as memantine, lanicemine, and nitrous oxide do not exert consistent antidepressant effects.
- Candidate biomarkers include plasma BDNF elevations in responders, reduced response in BDNF Val66Met carriers, plasma D-serine levels predicting response, sleep slow-wave activity increases, pro-cognitive effects at TRD doses, inflammatory/metabolic markers (IL-6, CRP, hsCRP, TNF-α, adiponectin, resistin, BMI, metabolic syndrome), and neuroimaging findings in prefrontal cortex, anterior cingulate cortex, hippocampus, and nucleus accumbens.
- Intranasal esketamine was FDA-approved in March 2019 for major depression failing two or more antidepressants; a phase III trial of over 200 patients showed significant improvement at 4 weeks, while two other phase III trials failed primary endpoints. Maintenance studies up to 88 weeks reported decreased relapse risk and reassuring safety data to over 1 year.
Methods
- Narrative review of ketamine as an antidepressant, covering pharmacology/pharmacokinetics, clinical trials, adverse effects, postulated mechanisms, and potential biomarkers.
- Literature search performed in PubMed/MEDLINE and Web of Science Core Collection for English-language papers from 2000 to 2019, using specified topics such as ketamine as an antidepressant, mechanisms of action, biomarkers, enantiomers/metabolites, inflammation, metabolism, sleep, adverse effects, cognition, and neuroimaging.
- Synthesis is qualitative; no systematic review, meta-analysis, or formal quality appraisal is described.
Limitations
- Stated in the paper: no long-term RCTs exist; many studies have small sample sizes; findings are contradictory for some mechanisms and biomarkers (e.g., 2R,6R-HNK, mTOR/rapamycin, opioid system); large head-to-head clinical comparisons of esketamine, R-ketamine, and racemic ketamine have not been reported; sleep data are limited to short-term intravenous infusions; neuroimaging data are limited by small samples and few investigations.
- Evident from the text: as a narrative review, it does not systematically assess study quality or pool results quantitatively, and much mechanistic evidence comes from animal models, so biomarker and mechanism conclusions remain preliminary.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
22 Valid · 3 Not valid · 124 Not checked · 31 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Following treatment with antidepressant drugs, only half of patients are noted to have a significant clinical response.6,7”
§ Ketamine as an antidepressant: overview of its mechanisms of action and potential predictive biomarkers > Introduction
What the sources say
- Supportedcites [6] Undurraga J Baldessarini RJ Randomized, placebo-controlled trials of antidepressants for acute major depression: thirty-year meta-analytic review. Neuropsychopharmacology 2012; 37: 851– 864. 22169941 PMC3280655 source
The Discussion reports a 54% crude response rate among participants receiving antidepressants in the reviewed trials, consistent with “only half.” The Outcome Measures section defines response as usually at least a 50% reduction in depression rating-scale scores. This finding concerns adults in trials for acute major depression. (LLM, conf=0.92)
- Not checked yetcites [7] Fava M Davidson KG Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am 1996; 19: 179– 200. 8827185 source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“A phase III trial of over 200 patients using esketamine adjunctive to an antidepressant demonstrated significant improvement in depression at 4 weeks compared with those using a placebo nasal spray.70”
§ Ketamine as an antidepressant: overview of its mechanisms of action and potential predictive biomarkers > Overview of the status of clinical trials with ketamine and its enantiomers
What the sources say
- Supportedcites [70] Popova V Daly EJ Trivedi M, et al Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study. Am J Psychiatry 2019; 176: 428– 438. 31109201 source
The opening Results passage reports that 227 patients were randomized. The Results section reports significantly greater improvement in depression scores at day 28 with esketamine plus an oral antidepressant than with an oral antidepressant plus placebo nasal spray (p=0.020). The Discussion identifies this as a phase 3 study. Page numbers were not supplied in our copy. (LLM, conf=0.93)
boostedstates a causen = 200- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“However, the literature on the antidepressant effects of 2R,6R-HNK is controversial, with several contradictory reports.41,48–52”
§ Ketamine as an antidepressant: overview of its mechanisms of action and potential predictive biomarkers > Basic chemistry, pharmacology and pharmacokinetics of ketamine
What the sources say
- Supportedcites [41] Yang C Yang J Luo A, et al Molecular and cellular mechanisms underlying the antidepressant effects of ketamine enantiomers and its metabolites. Transl Psychiatry 2019; 9: 280. PMC6838457 31699965 source
The (2R,6R)-HNK section (page not supplied) reports that several groups replicated its antidepressant-like effects in rodents, but the authors' group found no such effects in rodent models of depression. Those opposing findings support the description of the literature as controversial. (LLM, conf=0.93)
- Supportedcites [48] Zanos P Highland JN Liu X, et al (R)-ketamine exerts antidepressant actions partly via conversion to (2R,6R)-hydroxynorketamine, while causing adverse effects at sub-anaesthetic doses. Br J Pharmacol 2019; 176: 2573– 2592. 30941749 PMC8567221 source
The Discussion reports several studies finding rapid antidepressant-relevant actions of (2R,6R)-HNK and contrasts them with studies that failed to find such actions in animal tests. It also discusses dose differences as a possible explanation for the conflicting results. (LLM, conf=0.91)
- Supportedcites [49] Fukumoto K Fogaca MV Liu RJ, et al Activity-dependent brain-derived neurotrophic factor signaling is required for the antidepressant actions of (2R,6R)-hydroxynorketamine. Proc Natl Acad Sci USA 2019; 116: 297– 302. 30559184 PMC6320534 source
The Discussion explicitly notes discrepancies among reports of (2R,6R)-HNK’s antidepressant actions, particularly in stress and social-defeat models. It also says the reasons for those discrepancies are unclear. (LLM, conf=0.91)
- Not checked yetcites [50] Chou D Peng HY Lin TB, et al (2R,6R)-hydroxynorketamine rescues chronic stress-induced depression-like behavior through its actions in the midbrain periaqueductal gray. Neuropharmacology 2018; 139: 1– 12. 29953886 source
- Not checked yetcites [51] Xiong Z Fujita Y Zhang K, et al Beneficial effects of (R)-ketamine, but not its metabolite (2R,6R)-hydroxynorketamine, in the depression-like phenotype, inflammatory bone markers, and bone mineral density in a chronic social defeat stress model. Behav Brain Res 2019; 368: 111904. 30980851 source
- Supportedcites [52] Yamaguchi JI Toki H Qu Y, et al (2R,6R)-hydroxynorketamine is not essential for the antidepressant actions of (R)-ketamine in mice. Neuropsychopharmacology 2018; 43: 1900– 1907. 29802366 PMC6046044 source
The Introduction describes opposing reports on whether (2R,6R)-HNK has antidepressant effects in rodent models. The Discussion explicitly says the study's results contradict previously reported results and notes discrepancies between laboratories. Page numbers are not provided in our copy. (LLM, conf=0.92)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“This increase in SWA correlates strongly with increases in synaptic plasticity and plasma BDNF preclinically,135 and in ketamine-responsive MDD patients.113,133”
§ Ketamine as an antidepressant: overview of its mechanisms of action and potential predictive biomarkers > Other potential biomarkers for predicting response to ketamine > Sleep
What the sources say
- Not checked yetcites [135] Huber R Tononi G Cirelli C Exploratory behavior, cortical BDNF expression, and sleep homeostasis. Sleep 2007; 30: 129– 139. 17326538 source
- Supportedcites [113] Duncan WC Sarasso S Ferrarelli F, et al Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder. Int J Neuropsychopharmacol 2013; 16: 301– 311. 22676966 PMC3510337 source
The Results section 'Relationship between mood, BDNF, and slow wave sleep changes' reports that in the ketamine-responder subgroup (N=13) SWA (r=0.595, p=0.032) and slow wave amplitude (r=0.626, p=0.022) correlated significantly with change in log plasma BDNF, whereas non-responders (N=16) showed no such relationships; the whole-group correlation was r=0.45, p=0.014. The Abstract and Discussion frame SWA and individual slow wave parameters as surrogate markers of central synaptic plasticity/synaptic strength and state that the BDNF–slow wave link 'was strongest in the cohort of responders', supporting the claim's wording that SWA increases correlate with increases in synaptic plasticity and plasma BDNF in ketamine-responsive MDD patients. Only the magnitude adverb 'strongly' is slightly stronger than the paper's own 'significant/proportional/strongest in responders' language (r ≈ 0.6), and the preclinical clause of the citing sentence is attributed to a different reference (135), not this paper. (LLM, conf=0.84)
- Supportedcites [133] Duncan WC Jr Zarate CA Jr Ketamine, sleep, and depression: current status and new questions. Curr Psychiatry Rep 2013; 15: 394. 23949569 PMC3827949 source
The 'Effects of Ketamine on Sleep and Slow Waves in Treatment-Resistant MDD' section states that in patients who responded to ketamine (>50% MADRS reduction), 'changes in BDNF levels were proportional to changes in EEG slow wave parameters,' and that 'the observed correlations between BDNF levels and slow wave parameters indicate a strong relationship between these measures,' with slow wave slope increases 'consistent with increased synaptic strength.' The 'Sleep and Plasticity' section supplies the preclinical side: SWA is raised by intrahemispheric BDNF infusion and by behavioral interventions that increase central BDNF and plasticity-related genes (refs 9, 28), with SWA/slow wave slope treated as markers of synaptic strength. Both halves of the paraphrase — preclinical and ketamine-responsive MDD — are therefore carried by our copy of this review. (LLM, conf=0.87)
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“AMPA receptor activation appears to be a critical step in ketamine’s mechanism of action as co-administration of an AMPA receptor inhibitor abolished its antidepressant effects.96–98”
§ Ketamine as an antidepressant: overview of its mechanisms of action and potential predictive biomarkers > Antidepressant mechanisms of ketamine and potential biochemical biomarkers
What the sources say
- Supportedcites [96] Autry AE Adachi M Nosyreva E, et al NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 2011; 475: 91– 95. 21677641 PMC3172695 source
Passage [3] states that acute systemic NBQX alone did not affect forced-swim behaviour, but when co-applied with ketamine it 'abolished behavioural FST AD-like responses', and concludes that the behavioural antidepressant effects 'require ketamine-mediated augmentation of AMPA-receptor activation'. Passage [1] reinforces this ('increased AMPA-mediated neurotransmission underlies ketamine's AD-like behavioural effects'). The citing sentence is hedged ('appears to be a critical step'), which the source supports with equal or greater confidence. (LLM, conf=0.90)
- Not checked yetcites [97] Koike H Iijima M Chaki S Involvement of AMPA receptor in both the rapid and sustained antidepressant-like effects of ketamine in animal models of depression. Behav Brain Res 2011; 224: 107– 111. 21669235 source
- Not checked yetcites [98] Maeng S Zarate CA Jr Du J, et al Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry 2008; 63: 349– 352. 17643398 source
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
96 more claims · 6 with their cited sources checked
Create a free account to see all 180 claims and to verify the 206 references still open.
- It may state two separate claims as one. 61
- Probably not a substantial claim. 26
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition to glutamatergic modulation, ketamine is also an opioid (mu, kappa, delta) and dopamine receptor agonist, inhibits monoamine reuptake, and antagonizes muscarinic receptors [32].”
From Ketamine in neuropsychiatric disorders: an update (2024) · cites this paper as [32]
Experimental — accuracy not yet measured
Citations
Cites
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
mTOR Signaling in Growth, Metabolism, and Disease
Saxton, R. A., & Sabatini, D. M. (2017) · Cell · doi:10.1016/j.cell.2017.02.004 · Cited by 7,555
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Ferrari, A. J., Charlson, F. J., Norman, R. E., Patten, S. B., Freedman, G., Murray, C. J. L., Vos, T., & Whiteford, H. A. (2013) · PLoS Medicine · doi:10.1371/journal.pmed.1001547 · Cited by 3,115 · cited 2×
“an option for increasing accessibility of ketamine treatments for depression? J Clin Psychiatry 2020; 81(1): 19lr13146.”
BackgroundmTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881
mTOR Signaling in Growth, Metabolism, and Disease
Saxton, R. A., & Sabatini, D. M. (2017) · Cell · doi:10.1016/j.cell.2017.03.035 · Cited by 2,070
NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses
Autry, A. E., Adachi, M., Nosyreva, E., Na, E. S., Los, M. F., Cheng, P.-F., Kavalali, E. T., & Monteggia, L. M. (2011) · Nature · doi:10.1038/nature10130 · Cited by 1,926
Moghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793
NMDAR inhibition-independent antidepressant actions of ketamine metabolites
Zanos, P., Moaddel, R., Morris, P. J., Georgiou, P., Fischell, J., Elmer, G. I., Alkondon, M., Yuan, P., Pribut, H. J., Singh, N. S., et al. (2016) · Nature · doi:10.1038/nature17998 · Cited by 1,609
Research works printed but not linked: 3
- Baker G Mitchell N Depression, chemical mechanisms of. In: Begley T (ed.). Wiley encyclopedia of chemical biology. Hoboken, NJ: John Wiley and Sons, 2009.
- Muller J Pentyala S Dilger J, et al Ketamine enantiomers in the rapid and sustained antidepressant effects. Ther Adv Psychopharmacol 2016; 6: 185– 192. 27354907 PMC4910398 · DOI · Paper page
- Abdallah CG Averill LA Gueorguieva R, et al Rapamycin, an immunosuppressant and mTORC1 inhibitor, triples the antidepressant response rate of ketamine at 2 weeks following treatment: a double-blind, placebo-controlled, cross-over, randomized clinical trial. bioRxiv 2018: 500959.
Cited by
Items 101–200 of 214
Glavonic, E., Dragić, M., Mitić, M., Aleksic, M., Lukić, I., Ivković, S., & Adžić, M. (2024) · Pharmaceuticals · doi:10.3390/ph17060669 · Cited by 7
Mechanism of action of antidepressants
Sharma, K., Sundriyal, A., Loshali, A., Agrawal, M., Krishna, C. G., & Singh, Y. P. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-99855-0.00011-7 · Cited by 11
Mansoori, A., Bazrafshan, A., Ahmadi, J., & Mosavat, S. H. (2025) · Trials · doi:10.1186/s13063-025-08836-4 · Cited by 9
“Preclinical trials and systematic review further support its anxiolytic and anti-depressant effects, emphasizing its potential as a valuable treatment option for this unique patient population [11, 31, 34, 36].”
Gao, Z., Winhusen, T. M., Gorenflo, M. P., Dorney, I., Ghitza, U. E., Kaelber, D. C., & Xu, R. (2024) · Addiction · doi:10.1111/add.16715 · Cited by 8
Tamman, A. J. F., Anand, A., & Mathew, S. J. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2049754 · Cited by 7
Near-death experiences after cardiac arrest: a scoping review
Kovoor, J. G., Santhosh, S., Stretton, B., Tan, S., Gouldooz, H., Moorthy, S., Pietris, J., Hannemann, C., Yu, L. K., Johnson, R., et al. (2024) · Discover Mental Health · doi:10.1007/s44192-024-00072-7 · Cited by 10
Levinstein, M. R., Schoenborn, I., Manza, P., Schatzberg, A. F., Zarate, C. A., Bonaventura, J., & Michaelides, M. (2025) · Biological Psychiatry · doi:10.1016/j.biopsych.2025.11.021 · Cited by 6
Therapeutic potential of cannabidiol in depression
Guldager, M. B., Filho, A. M. C., Biojone, C., & Joca, S. R. L. (2024) · International review of neurobiology · doi:10.1016/bs.irn.2024.06.001 · Cited by 7
Escobedo-Aedo, P. J., Serrand, C., Kabani, S., & Estric, C. (2025) · Journal of Eating Disorders · doi:10.1186/s40337-025-01232-y · Cited by 6
Ketamine as a Novel Psychopharmacotherapy for Eating Disorders: Evidence and Future Directions
Ragnhildstveit, A., Slayton, M., Jackson, L., Brendle, M., Ahuja, S., Holle, W., Moore, C., Sollars, K., Seli, P., & Robison, R. (2022) · doi:10.20944/preprints202202.0156.v1 · Cited by 36
Ketamine retards recovery from reward downshift and supports conditioned taste aversion
Agüera, A. D. R., Cándido, C., Donaire, R., Papini, M. R., & Torres, C. (2023) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2023.173671 · Cited by 4
Sakopoulos, S., & Hinz, L. D. (2024) · Psychoactives · doi:10.3390/psychoactives3040031 · Cited by 5
Nakajima, W., Hatano, M., Ohtani, Y., Tani, H., Yatomi, T., Tsuchimoto, S., Fujimoto, Y., Eiro, T., Ichijo, S., Nakano, K., et al. (2026) · Molecular Psychiatry · doi:10.1038/s41380-026-03510-w · Cited by 6
Ketamine as a Novel Psychopharmacotherapy for Eating Disorders: Evidence and Future Directions
Ragnhildstveit, A., Slayton, M., Jackson, L., Brendle, M., Ahuja, S., Holle, W., Moore, C., Sollars, K., Seli, P., & Robison, R. (2022) · doi:10.20944/preprints202202.0156.v2 · Cited by 36
Alibudbud, R. C. (2022) · Clinical Epidemiology and Global Health · doi:10.1016/j.cegh.2022.101211 · Cited by 5
Zhang, X., Huang, M., Wangyang, X., Leiming, D., Yu, Y., & Zeng, J. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.120133 · Cited by 4
Understanding the variability in ketamine’s efficacy in managing treatment-resistant depression
Bryan, J. (2024) · Discover Psychology · doi:10.1007/s44202-024-00277-5 · Cited by 3
Suleman, S., Anzar, N., Ansari, S., et al. (2025) · Microchimica Acta · doi:10.1007/s00604-025-07429-x · Cited by 3
The evidence for ketamine treatment in older adults with psychiatric illness: a scoping review
Murphy, K. S., Golden, J. C., Schuster, H., & Tampi, R. R. (2025) · Therapeutic Advances in Chronic Disease · doi:10.1177/20406223251384803 · Cited by 3
Tóth, A., Sviatkó, K., Détári, L., & Hajnik, T. (2023) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2023.173556 · Cited by 3
Bulek, D., & BaDour, S. (2026) · Journal of Neurophysiology · doi:10.1152/jn.00516.2025 · Cited by 3
Wang, C., Yu, Q., Li, D., Sun, N., Huang, Y. Y., Zhang, Y., & Zhou, W. (2021) · Neurochemical Research · doi:10.1007/s11064-021-03380-4 · Cited by 3
Serotonin is a Common Thread Linking Different Classes of Antidepressants
Witt, C. E., Mena, S., Holmes, J., Hersey, M., Buchanan, A. M., Parke, B., Saylor, R., Honan, L. E., Berger, S. N., Lumbreras, S., et al. (2023) · doi:10.21203/rs.3.rs-2741902/v1 · Cited by 18
Heroiu, I., Le, G. H., Sioufi, M., Dri, C. E., Zheng, Y. J., Wong, S., & McIntyre, R. S. (2026) · Clinical Neuropharmacology · doi:10.1097/wnf.0000000000000692 · Cited by 2
Shah, A. A., Sawaira, F., Misbahuddin, Mohmand, M. S., Khan, S., Bacha, Z. A. R. Y. A. B., Iftikhar, H., Jamal, A., Khattak, F., Khalid, A. A., et al. (2026) · Brain and Behavior · doi:10.1002/brb3.71255 · Cited by 2
Arena, Á. R., Rubinstein, M. R., Genaro, A. M., Tifner, V., Risnik, D., López-Carvajal, J. E., Daray, F. M., Silva, E. A. C., & Errasti, A. E. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03338-w · Cited by 6
Recent Updates in Obstetric Analgesia
Beg, T., Daoud, B. E., & Angelo, T. E. (2021) · Indian Journal of Pain · doi:10.4103/ijpn.ijpn_81_21 · Cited by 4
The Habenula’s role in major depressive disorder: recent insights from preclinical and human studies
Lin, F., Casmey, K., Codeluppi-Arrowsmith, S. A., & Turecki, G. (2026) · Translational Psychiatry · doi:10.1038/s41398-026-03867-0 · Cited by 5
Role of the Pharmacist in Managing Treatment-Resistant Depression: A Focus on Ketamine
Liu, L. X. Y., Golts, M., & Fernandes, V. (2021) · Pharmacy · doi:10.3390/pharmacy9030118 · Cited by 2
The role of ketamine as an antidepressant agent
Senapathi, T. G. A., Widnyana, M. G., Aryani, L. N. A., & Ryalino, C. (2023) · Bali Journal of Anesthesiology · doi:10.4103/bjoa.bjoa_81_23 · Cited by 3
Wei, H., Liu, J., Lu, Y., Bhuiyan, P., Gruttner, J., Louis, L. S., Yi, Y., & Liang, G. (2025) · doi:10.21203/rs.3.rs-6254774/v1 · Cited by 2
The Promise of Psychedelic Research
Peritore, C. (2022) · Future Drug Discovery · doi:10.4155/fdd-2021-0012 · Cited by 3
McNaughton, N., & Gray, J. A. (2024) · Oxford University Press eBooks · doi:10.1093/oso/9780198843313.003.0012 · Cited by 2
Filipović, D., & Turck, C. W. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05013-1 · Cited by 5
Nepton, A., Farahani, H., Williams, M. T., Booij, L., & Faber, S. C. (2024) · Journal of Psychedelic Studies · doi:10.1556/2054.2024.00343 · Cited by 2
Intranasal esketamine: A primer
Price, M. Z. (2023) · Current Psychiatry · doi:10.12788/cp.0352 · Cited by 2
Murata, S., Madaj, Z., Capan, C. D., Sheldon, R. D., El‐Mallakh, R. S., Parikh, S. V., Bobo, W. V., Goes, F. S., Wolkowitz, O. M., Voort, J. L. V., et al. (2025) · Biological Psychiatry Global Open Science · doi:10.1016/j.bpsgos.2025.100503 · Cited by 7
Liu, J., Lu, Y., Bhuiyan, P., Gruttner, J., St. Louis, L., Yi, Y., Liang, G., & Wei, H. (2026) · Translational Psychiatry · doi:10.1038/s41398-026-03816-x · Cited by 2
Liu, J., Lü, Y., Bhuiyan, P., Gruttner, J., Louis, L. S., Yi, Y., Liang, G., & Wei, H. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.09.06.611461 · Cited by 2
Shenoy, S., Belle, V. S., Munoli, R. N., Sharma, M., & Praharaj, S. K. (2026) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2026.105014 · Cited by 2
Özler, C., Özkan, E., Shomalizadeh, N., Kesibi, J., Sapancı, S., Akpunar, F., Uçar, E. A., & Özdemir, Y. (2025) · Experimental Brain Research · doi:10.1007/s00221-025-07085-w · Cited by 1
Psychedelic Use and Intimacy: A Systematic Review of Experimental and Naturalistic Research
Bradford, A., Freedman, E., & Dinero, R. E. (2025) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2025.2577311 · Cited by 2
Long-term relief of CRPS-associated limb dystonia with ketamine infusion
AlZahrani, A., Weber-Adrian, D., & Ong, M. C. (2026) · BMJ Case Reports · doi:10.1136/bcr-2025-269687 · Cited by 1
Cao, Q., Zhang, N., Leng, C., Wang, S., & Ma, J. (2025) · Reviews in Medical Virology · doi:10.1002/rmv.70036 · Cited by 2
Fundamentals of the septo-hippocampal system
McNaughton, N., & Gray, J. A. (2024) · Oxford University Press eBooks · doi:10.1093/oso/9780198843313.003.0009 · Cited by 1
The Use of Prophylactic Ketamine to Mitigate Postoperative Depressive Symptoms: A Systematic Review
Yip, E., & Fleck, D. A. (2024) · Journal of PeriAnesthesia Nursing · doi:10.1016/j.jopan.2024.05.026 · Cited by 1
Research trends in esketamine for depression over the past decade: a bibliometric analysis
Zhang, B., Liu, Y., Zheng, J., & Chen, J. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1621830 · Cited by 2
Psychedelic Healing: A Historical, Empirical, and Personal Account
Swoap, R. (2023) · American Journal of Health Promotion · doi:10.1177/08901171231210806e · Cited by 3
Martire, G., Sipple, D., Baron, D. A., Gold, M. S., Lewandowski, K.-U., Dennen, C. A., Sharafshah, A., Elman, I., Thanos, P. K., Modestino, E. J., et al. (2024) · PubMed · Cited by 2
Role of Glial Cells in Depression and Drug Addiction
Tizabi, Y., Getachew, B., Hauser, S. R., Tsytsarev, V., Manhães, A. C., & da Silva, V. D. A. (2024) · doi:10.20944/preprints202405.0173.v1 · Cited by 27
Vojvodić, S., Katona, G., & Sarač, M. S. (2021) · Medicinski pregled · doi:10.2298/mpns2104117v · Cited by 3
Pharmacokinetics and pharmacodynamics of orally administered S-ketamine in healthy participants
van Mechelen, J., Wieles, T., Borghans, L. G. J. M., Otto, M. E., Juachon, M. J., Gillespie, A. L., van Noorden, M. S., Harmer, C. J., van Hemert, A. M., van Gerven, J. M. A., et al. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811261456187 · Cited by 4
Nagamine, T. (2024) · World Journal of Clinical Cases · doi:10.12998/wjcc.v12.i36.6883 · Cited by 1
Memory and the septo-hippocampal system
McNaughton, N., & Gray, J. A. (2024) · Oxford University Press eBooks · doi:10.1093/oso/9780198843313.003.0008 · Cited by 1
Barzkar, M., Alavi, K., Malakouti, K., Khajeh-Azad, M.-A., Barzkar, F., Jalali Nadoushan, A. H., & Lahiji, M. N. (2025) · BMC Research Notes · doi:10.1186/s13104-024-07029-7 · Cited by 1
“Ketamine at subanesthetic doses is the only FDA-approved antidepressant with its onset of action within a few hours [5].”
Evaluating passive physiological data collection during Spravato treatment
Solomon, T. M., Hajduk, M., Majernik, M., Jemison, J., Deschamps, A., Scoggins, J., Kolar, A., Pinheiro, M. A., Dubec, P., Skala, O., et al. (2023) · Frontiers in Digital Health · doi:10.3389/fdgth.2023.1281529 · Cited by 1
Bloy, C., Sarma, A., Marsh, B., Hardy, L., Grabski, M., Mollaahmetoğlu, Ö. M., Shotton, J., Bhaskaran, S., Lingford-Hughes, A. R., Curran, H. V., et al. (2026) · Addiction · doi:10.1111/add.70320 · Cited by 2
Zhong, W., Rao, M., Zhou, Q., Leng, Z., Zhang, B., & Lin, Z. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1904032
Hepatobiliary Complications Associated With Ketamine Use: Clinical Insights and Future Directions
Waheed, H. W., Ashraf, M. R., Sajjad, T., Jehangir, H., Baig, I., Zulaid, A., Nasir, A. R., & Dad, A. (2025) · Cureus · doi:10.7759/cureus.84974 · Cited by 3
McNaughton, N., & Gray, J. A. (2024) · Oxford University Press eBooks · doi:10.1093/oso/9780198843313.003.0015
Anesthetic Concerns in Psychiatric Disease
Martinez-Baladejo, M. T., Liongson, F. A. Z., Wong, D., Spoleti, C., Suyumov, D., Menghani, S. V., McCarthy, C., Divito, A. J., Daniel, S. V., Salpekar, S., et al. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.110173 · Cited by 2
Basic aspects of ketamine therapy for treatment-resistant depression - a review paper
Szafrańska, W., Poborowska, D., Gańko, T., Kahan, W., Bąk, E., Fordymacki, J., Wojaczek, M., Polańska, K., & Najjar, O. (2024) · Quality in Sport · doi:10.12775/qs.2024.19.53331
Williamson, S. F., Grayling, M. J., Mander, A., Noor, N. M., Savage, J., Yap, C., & Wason, J. M. S. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4077740
McNaughton, N., & Gray, J. A. (2024) · Oxford University Press eBooks · doi:10.1093/oso/9780198843313.002.0004
Ketamine for Treatment-Resistant Depression
Madhloom, R. S. (2021) · Mustansiriya Medical Journal · doi:10.4103/mj.mj_15_21
The Role of Rapid-Acting Antidepressants in Suicidal Crisis Management
Lengvenytė, A., Sarchiapone, M., Iosue, M., & Courtet, P. (2024) · Cambridge University Press eBooks · doi:10.1017/9781009067287.016
Ramm, R., Wiisanen, M., & DeMarco, M. (2025) · Oxford University Press eBooks · doi:10.1093/med/9780197760864.003.0005
Symptoms and syndromes of anxiety
McNaughton, N., & Gray, J. A. (2024) · Oxford University Press eBooks · doi:10.1093/oso/9780198843313.003.0013
Thanoon, T. B., & Althanoon, Z. A. (2024) · Review of Clinical Pharmacology and Pharmacokinetics - International Edition · doi:10.61873/xevc6813 · Cited by 1
McNaughton, N., & Gray, J. A. (2024) · Oxford University Press eBooks · doi:10.1093/oso/9780198843313.003.0001 · Cited by 1
Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery
Tanaka, M. (2026) · Biomedicines · doi:10.3390/biomedicines14061265
Hu, B., Ortiz-Cruz, A., Sachidanandan, R. F., Ramiro, C., & Bourgeois, J. A. (2026) · Journal of the Academy of Consultation-Liaison Psychiatry · doi:10.1016/j.jaclp.2026.09.005
Effects of Ketamine and Esketamine on Cognitive Functions in Treatment-Resistant Depression
Mutlu, M., Öven, Ç., Kurt, B. S., & SUNAY, E. (2025) · Psikiyatride Guncel Yaklasimlar - Current Approaches in Psychiatry · doi:10.18863/pgy.1524106
Yıldırım, C., Aydın, S., Öner, S., & Kılıç, F. S. (2026) · Ankara Üniversitesi Tıp Fakültesi Mecmuası · doi:10.65092/autfm.1830160
List of online appendices and reviews
McNaughton, N., & Gray, J. A. (2024) · Oxford University Press eBooks · doi:10.1093/oso/9780198843313.002.0010
McNaughton, N., & Gray, J. A. (2024) · Oxford University Press eBooks · doi:10.1093/oso/9780198843313.002.0011
Artin, H., Bentley, S., Mehaffey, E., Liu, F. X., Sojourner, K., Bismark, A. W., PRINTZ, D. J., Lee, E., Martis, B., Peralta, S. D., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3928508
A theory of the septo-hippocampal system (SHS)
McNaughton, N., & Gray, J. A. (2024) · Oxford University Press eBooks · doi:10.1093/oso/9780198843313.003.0010
Jucha, D., Klimas, M., Wiśniewska, D., Winiarska, M., Szczupak, M., Kobak, J., & Krupa-Nurcek, S. (2026) · Biomedicines · doi:10.3390/biomedicines14061185
Emergence of Ketamine as a Rapid Acting Antidepressant: Mechanistic Insights and Future Directions
Singh, A., & Bedi, P. M. S. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.99765
da Silva, F. A., Avelar, R. S., Peixoto, B., Bacelar–Nicolau, L., Santos, F., Ribeiro, J. C., & Heitor, M. J. (2026) · Brain and Behavior · doi:10.1002/brb3.71164 · Cited by 1
Liu, J., Liang, Z., Wang, H., Chen, S., Xie, Y., Xing, F., Wang, Z., Yang, J., & Yuan, J. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s562398 · Cited by 1
Fármacos enteógenos y la depresión resistente al tratamiento: Una revisión narrativa
Herrera-Solís, A., Morelos, J. C., Ruiz‐Contreras, A. E., Méndez‐Díaz, M., Ortega-Gómez, A., & Prospero-Garcia, O. E. (2024) · PSICUMEX · doi:10.36793/psicumex.v14i1.628 · Cited by 1
McNaughton, N., & Gray, J. A. (2024) · Oxford University Press eBooks · doi:10.1093/oso/9780198843313.002.0005
McNaughton, N., & Gray, J. A. (2024) · Oxford University Press eBooks · doi:10.1093/oso/9780198843313.003.0003
McNaughton, N., & Gray, J. A. (2024) · Oxford University Press eBooks · doi:10.1093/oso/9780198843313.002.0006
A single S-ketamine injection enhances mTOR signaling in rat skeletal muscle
Skriver, S. A., Arjmand, S., Andersen, A. B., Wegener, G., & Hansen, M. (2026) · Journal of Muscle Research and Cell Motility · doi:10.1007/s10974-025-09720-z
Ketamine and Evolving Neuroplasticity
Prabakar, A. (2026) · Clinical Drug Investigation · doi:10.1007/s40261-026-01565-9
The neurology of anxiety—planning circuits
McNaughton, N., & Gray, J. A. (2024) · Oxford University Press eBooks · doi:10.1093/oso/9780198843313.003.0011
A conceptual theory of the goal inhibition system
McNaughton, N., & Gray, J. A. (2024) · Oxford University Press eBooks · doi:10.1093/oso/9780198843313.003.0005
(2025) · The Egyptian Journal of Hospital Medicine · doi:10.21608/ejhm.2025.421423
Duncan, E., Hersant, H., & Khairova, R. A. (2026) · Springer eBooks · doi:10.1007/978-3-032-15772-0_4
Dreaming and psychiatric disorders
Hardin, K. A., Hussanuddin, H., Husaini, S. S., & Stamm, D. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-822963-7.00375-3
Akhtar, M. J., Balushi, K. A. A., Sabahi, B. A., Khan, S. A., & Tamimi, A. A. (2025) · RSC Medicinal Chemistry · doi:10.1039/d5md00473j
Pardo, S. G., Boada, L. B. G. L., & Lopez-Munoz, F. J. (2023) · Archivos de Medicina (Manizales) · doi:10.30554/archmed.23.1.4532.2023
Chawla, G., Pradhan, T., Alam, N., Kunzang, S., & Gupta, O. (2026) · Archiv der Pharmazie · doi:10.1002/ardp.70251 · Cited by 2
The neurology of anxiety—survival circuits
McNaughton, N., & Gray, J. A. (2024) · Oxford University Press eBooks · doi:10.1093/oso/9780198843313.003.0006
Metadata
- Authors
- Matveychuk, D., Thomas, R. K., Swainson, J., Khullar, A., MacKay, M.-A., Baker, G. B., & Dursun, S. M.
- Affiliations
- University of Alberta (CA)
- Corresponding author
- Baker, Glen B.
- Venue
- Therapeutic Advances in Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2020-01
- Volume
- 10
- Pages
- 2045125320916657-2045125320916657
- ISSN
- 2045-1253 (ISSN-L)
- 2045-1261
- PMC
- PMC7225830
- OpenAlex
- W3025130047
- Cited by
- 209
- References
- 224
- Citations by year
- 2026: 24 · 2025: 27 · 2024: 59 · 2023: 33 · 2022: 41 · 2021: 22 · 2020: 3
- FWCI
- 14.83
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Therapeutic Advances in Psychopharmacology (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- university of alberta (TRPGB-UAB)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- ketamine, major depressive disorder, treatment-resistant depression, rapid antidepressant effects, NMDA receptor, AMPA receptors, glutamate modulation, brain-derived neurotrophic factor, mTOR signaling, synaptic plasticity, predictive biomarkers, antidepressant response prediction, suicide prevention, neuroimaging biomarkers, cognitive biomarkers, inflammatory markers, metabolic biomarkers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
